Different responses to gefitinib in lung adenocarcinoma coexpressing mutant-and wild-type epidermal growth factor receptor genes
WC Chou, SF Huang, KY Yeh, HM Wang… - Japanese journal of …, 2006 - academic.oup.com
WC Chou, SF Huang, KY Yeh, HM Wang, MY Liu, JJ Hsieh, YC Cheung, JWC Chang
Japanese journal of clinical oncology, 2006•academic.oup.comResponse to gefitinib is strongly associated with the status of the epidermal growth factor
receptor gene. Here we report the different treatment responses in a case of lung
adenocarcinoma coexpressing mutant-type gene in the primary lung mass and a wild-type
gene in the metastatic bone lesions. This case demonstrated that at least two strains of
tumor cells were present in a single patient. This may be one of the mechanisms of gefitinib
resistance.
receptor gene. Here we report the different treatment responses in a case of lung
adenocarcinoma coexpressing mutant-type gene in the primary lung mass and a wild-type
gene in the metastatic bone lesions. This case demonstrated that at least two strains of
tumor cells were present in a single patient. This may be one of the mechanisms of gefitinib
resistance.
Abstract
Response to gefitinib is strongly associated with the status of the epidermal growth factor receptor gene. Here we report the different treatment responses in a case of lung adenocarcinoma coexpressing mutant-type gene in the primary lung mass and a wild-type gene in the metastatic bone lesions. This case demonstrated that at least two strains of tumor cells were present in a single patient. This may be one of the mechanisms of gefitinib resistance.
Oxford University Press
以上显示的是最相近的搜索结果。 查看全部搜索结果